SuperworthSurrozen EPS SRZN
Diluted earnings per share by quarter and over the last twelve months, from 2020.
- Last 12 months, to Jun 30, 2026
- −$40.55
- Latest quarter, Q2 FY26
- −$0.41
- −116% on a year earlier
- Fiscal year 2025
- −$33.37
Surrozen's earnings per share was −$40.55 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.41, down 116% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$33.37 | n/a |
| FY2024 | −$21.29 | n/a |
| FY2023 | −$21.36 | n/a |
| FY2022 | −$15.45 | n/a |
| FY2021 | −$35.25 | n/a |
| FY2020 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.41 | −116% | −$40.55 | |
| Q1 FY26 | −$11.65 | n/a | −$37.59 | |
| Q4 FY25 | −$20.13 | n/a | −$33.37 | |
| Q3 FY25 | −$8.36 | n/a | −$21.86 | |
| Q2 FY25 | $2.55 | n/a | −$13.94 | |
| Q1 FY25 | −$7.43 | n/a | −$24.48 | |
| Q4 FY24 | −$8.62 | n/a | −$21.29 | |
| Q3 FY24 | −$0.44 | n/a | −$17.05 | |
| Q2 FY24 | −$7.99 | n/a | −$21.75 | |
| Q1 FY24 | −$4.24 | n/a | −$18.44 | |
| Q4 FY23 | −$4.38 | n/a | −$21.36 | |
| Q3 FY23 | −$5.14 | n/a | −$17.28 |
Against its peers
Companies in Biotechnology nearest Surrozen's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| SRZNSurrozen | −$40.55 | |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| MGTXMeiraGTx | $0.71 | |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| Peer median | $0.58 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Surrozen
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.